< View all reports

PharmaFocus: Supportive Care in Oncology

There is an agreement among KOLs in the 7MM that supportive oncology has not been prioritised by physicians and institutions in the past.

This has been improving in recent years with the increasing appreciation of the importance of supportive care. Supportive care in oncology is a broad term composed of indications that are either a symptom of a patient’s cancer or a side effect of cancer treatment. This report focuses on six prominent cancer supportive care indications: chemotherapy-induced nausea and vomiting (CINV), cancer cachexia, oral mucositis, bone metastases, chemotherapy-induced neutropenia (CIN), and chemotherapy-induced anemia (CIA). This report is part of our Biosimilars market series.

  • Report Scope:
  • Key Opinion Leaders (KOLs) offer views on the past, present, and future trends in supportive care in oncology
  • Epidemiological insight on cancer and cancer supportive care
  • Overview of market landscape and available therapies
  • Unmet needs and opportunities identified in each indication

Traditionally an overlooked field, supportive oncology is growing across the 7MM (US, France, Germany, Italy, Spain, UK and Japan) and this growth will continue in the next 5-10 years.

Evidence suggests that supportive care increases the likelihood of finishing treatment, without the need for dose reductions or pauses in treatment. It can also reduce costs for healthcare institutions and improve quality of life for patients—all of which will become increasingly important as patients continue to live longer, and cancer becomes more like a chronic disease.

Despite oncology trends towards targeted therapies and new modalities of treatment such as immunotherapies, KOLs agree that chemotherapy will remain the backbone of cancer treatment for the next 5-10 years. Therefore, as the incidence of cancer rises, so will cases of chemotherapy-related conditions, in addition to a rise in general oncology-related conditions.


Purchase Today

Single user $ 4,995

Buy Now

+44 (0) 161 359 5813

Not ready to buy yet? Download our free report series guide on the Biosimilars Market

I consent to GlobalData collecting my details provided via this form.

You are in control of the communications you receive from us and you can update your preferences anytime to make sure you are receiving information that matters to you. Please check our GlobalData Privacy Policy to see how we protect and manage your submitted data.